Back to results
US 7,598,027 B2Granted
Botulinum toxin screening assays
AssigneeAllergan, Inc.
InventorsEster Fernandez-Salas, Patton E. Garay, Kei Roger Aoki
Life of this patent
Estimating the term…
Abstract
Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.
Claims29
A method of detecting Botulinum toxin serotype A (BoNT/A) activity in a sample, the method comprising the steps of:
- a) contacting a sample to a cell that contains an exogenous Fibroblast Growth Factor Receptor 3 (FGFR3) and an endogenous synaptosome-associated protein of 25000 Daltons (SNAP-25), wherein said cell is genetically engineered to express a nucleic acid molecule encoding said FGFR3;
- and wherein said cell is capable of BoNT/A intoxication;
- and
- b) detecting the presence of BoNT/A activity of said cell relative to a control cell by detecting the presence of endogenous SNAP-25 cleavage product from said cell.
1 more element
Dependencies are inferred from the claim text.